Corcept Therapeutics sinks after saying Phase 3 RELIANT trial of relacorilant combo does not justify further study as a treatment for end-stage pancreatic cancer Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- GameStop (GME) up 8% after announcing that it has completed its previously announced at-the-market equity offering program to sell up to a maximum of 5M shares
- Kaixin Auto (KXIN) up 8% after announcing that the company is in discussion with a Chinese RV retailer about cooperation and joint venture in exploring the RV market in China
- Splunk (SPLK) up 8% after announcing that Silver Lake will make a $1B investment in convertible senior notes
- Mudrick Capital Acquisition Corporation II (MUDS) up 4% after Topps reported Q1 earnings and provided FY21 guidance
UP AFTER EARNINGS -
- Cognyte (CGNT) up 3%
- Korn/Ferry (KFY) up 4%
LOWER -
- Corcept Therapeutics (CORT) down 9% after announcing the apparent level of benefit of its Phase 3 RELIANT trial of relacorilant combined with nab-paclitaxel does not justify its further study as a treatment for end-stage pancreatic cancer
- Anavex (AVXL) down 7% after a $50M registered direct offering at $21 per share
- MicroVision (MVIS) down 10% after entering into a $140M at-the-market equity offering
- AFC Gamma (AFCG) down 8% after announcing an offering of 2.75M shares of common stock
- Focus Financial (FOCS) down 9% after a 7.42M share spot secondary priced at $50.30
Symbols:
GME - $200.10 /
-13.82 (-6.46%)
KXIN MUDSMudrick Capital Acquisition Corporation II
SPLK CGNT KFY AVXL MVIS AFCG CORT Keywords: Fly Intel, Wall Street, Top Stories, Stocks